Kishan Patel,Alison Moskowitz
Kishan Patel
Combined modality therapy (cytotoxic chemotherapy followed by consolidative radiation [RT]) has historically been the standard-of-care for patients with early-stage Hodgkin lymphoma (HL). However, novel agents, such as brentuximab vedotin (...
Carrie Sha,Sarah C Rutherford
Carrie Sha
Outcomes for older patients with classic Hodgkin lymphoma (cHL) are improving with the inclusion of novel agents into frontline therapy. The sequential brentuximab vedotin (BV) and doxorubicin, vinblastine, dacarbazine (AVD) regimen was sta...
Alexandra D Dreyfuss,Joachim Yahalom
Alexandra D Dreyfuss
Radiation therapy (RT) has played a central role in the management of classic Hodgkin lymphoma (cHL) for over a century and remains an integral component of modern, risk-adapted treatment strategies. Advances in systemic therapy, molecular ...
Daniel Klein Reef,Natalie Sophia Grover
Daniel Klein Reef
The CD30 antibody-drug conjugate, brentuximab vedotin, and PD-1 inhibitors, nivolumab and pembrolizumab have transformed the care of patients with Hodgkin lymphoma and have been incorporated into earlier lines of therapy. However, there are...
New Tools and Drugs Improve the Balance Between Cure and Toxicity in Hodgkin Lymphoma [0.03%]
新的工具和药物改善了霍奇金淋巴瘤治疗的疗效和毒副反应之间的平衡
Alex F Herrera,Alison J Moskowitz
Alex F Herrera
New Developments in Hodgkin's Lymphoma: Outcomes and Disparities in Classic Hodgkin Lymphoma [0.03%]
经典霍奇金淋巴瘤的疗效及差异性研究新进展
Katia M Crisler,Mallorie B Heneghan,Justine M Kahn
Katia M Crisler
Despite continued advances, survival among patients with Hodgkin lymphoma differs by age, race and ethnicity, socioeconomic status, insurance, and treatment location. Inequities are evident across the cancer care continuum, from timely diag...
Michael A Spinner,Ranjana H Advani
Michael A Spinner
Hodgkin lymphoma is the most common hematologic malignancy diagnosed during pregnancy, attributed to overlapping peak incidence with the reproductive years. Management during pregnancy requires a multidisciplinary team including hematology/...
Hanan Alharthy,Sairah Ahmed
Hanan Alharthy
Stem cell transplantation remains a cornerstone in managing relapsed/refractory classic Hodgkin lymphoma, though its role is evolving with the integration of targeted therapies. Autologous stem cell transplantation achieves cure rates of 50...
New Standards in Advanced-stage Hodgkin Lymphoma: Selecting a Novel Regimen [0.03%]
经典复发难治霍奇金淋巴瘤的治疗进展及选择
Hunter Cassidy Cochran,Nancy L Bartlett
Hunter Cassidy Cochran
The management of advanced-stage Hodgkin lymphoma has entered an era defined by immune-based therapy. Nivolumab-AVD has become the preferred frontline regimen, delivering high cure rates with minimal toxicity across age groups. BrECADD rema...
Circulating Tumor DNA Assessment in Classic Hodgkin Lymphoma: Ready for Primetime? [0.03%]
经典霍奇金淋巴瘤的循环肿瘤DNA检测：准备就绪了吗？
Tanja Zamrik,Bastian von Tresckow,Stefan K Alig
Tanja Zamrik
Circulating tumor DNA (ctDNA) has emerged as a promising biomarker in classic Hodgkin lymphoma (cHL). Abundant ctDNA shedding from Hodgkin/Reed-Sternberg cells enables comprehensive molecular profiling directly from plasma. Recent studies h...